



CRESCENT

Crescent Private Credit Income Corp. Overview

March 2025

This sales and advertising literature is neither an offer to sell nor a solicitation of an offer to buy securities. An offering is made only by a prospectus. **This sales and advertising literature must be read in conjunction with the Prospectus in order to fully understand all of the implications and risks of the offering of securities to which the Prospectus relates. Please carefully read the Prospectus and consider CPCI's investment objectives, risks, charges and expenses and other information described therein prior to making any investment decisions. A copy of the Prospectus must be made available to you in connection with any offering.** No offering is made except by a prospectus filed with the Department of Law of the State of New York. Neither the U.S. Securities and Exchange Commission, the Attorney General of the State of New York nor any other state securities regulator has approved or disapproved our common stock, determined if the Prospectus is truthful or complete or passed on or endorsed the merits of the offering. Any representation to the contrary is a criminal offense.

Important Notices

Confidential Private Information

The information contained in this presentation is being furnished on a confidential basis for the purpose of providing certain information about Crescent Private Credit Income Corp. ("CPCI") and Crescent Capital Group LP and its predecessor entities ("Crescent" or the "Firm"). This presentation contains confidential and proprietary information and may not be copied; nor may it be transferred to any other third party without our prior written consent, and shall be returned at our request. Your receipt of this presentation is conditioned on your full agreement not to share the information disclosed in the presentation with any person who is not also legally or contractually obligated to maintain the confidentiality of the information. The information contained in this presentation is for informational purposes only, does not constitute a recommendation to acquire securities of CPCI, and is not intended to be used as the basis for making any investment decision.

This presentation contains information derived from a number of sources and while Crescent believes it to be reliable, neither the Firm, its general partners, investment advisors and affiliates make any representation as to the accuracy or completeness of such information. The materials contained herein are intended to supplement discussion between Crescent, on the one hand, and the recipients, on the other, and the supplemental discussions are required for these materials to be meaningful and complete. Footnotes and endnotes contain important information about the definition of terms used herein, the composition of the portfolios presented and related performance information as well as relevant in important disclosures and should be carefully reviewed.

Material Non-Public Information

The information shared in this presentation is highly proprietary, and in some circumstances, may constitute material non-public information in connection with the publicly traded securities of Crescent Capital BDC, Inc. and fund portfolio companies. Each recipient of this presentation also agrees that he/she (and their representatives and any person with whom they share the information) shall not use the information received in the presentation for purposes of trading in securities. In the event that a recipient transmits such information mistakenly or otherwise or becomes legally required (or reasonably determines that he/she is legally required) to disclose such information, such recipient shall, to the fullest extent permitted by law, promptly notify Crescent in writing of any such disclosure so that Crescent may seek a protective order or other appropriate remedy.

Not an Offer to Sell or Solicit an Offer to Buy

Nothing in this presentation constitutes an offer to sell or the solicitation of an offer to

buy securities. The information in these materials is provided solely as reference material with respect to Crescent, its people and advisory services business, as an independent asset management company. Any offer to sell or solicitation of an offer to buy a security may only be made by a separate private placement memorandum or prospectus with respect to that security.

Past Performance

Past performance does not predict future returns.

This presentation contains information about the performance of investments previously made by Crescent Funds or strategies advised or managed by the Firm. This information has not been audited or verified by an independent party. Performance information contained herein is based in significant part on unrealized investment valuations which may not be achieved.

CPCI may not replicate the historical performance achieved by Crescent. In addition, an investment in CPCI will be discrete from an investment in any other fund or account managed by Crescent (a "Crescent Fund"). As such, neither the realized returns nor the unrealized values attributable to one Crescent Fund are directly applicable to an investment in any other Crescent Fund. CPCI's primary focus in making investments may differ from those of existing Crescent Funds. Past performance should not be relied upon as an indication of future results. There can be no guarantee that CPCI will replicate the historical performance of Crescent or the historical performance of any Crescent Fund.

Returns may increase or decrease as a result of currency fluctuations.

Performance Targets and Returns

Cautionary note on relying primarily upon target performance or return in making an investment decision.

Investment performance targets and returns are aspirational and are presented as Crescent's expectations about how CPCI or any strategy described herein is intended to perform as well as the relative risk of CPCI and its investments, with the higher targets reflecting greater risk. Performance targets and returns are not promissory in nature. There can be no assurance that the targets will be realized or that CPCI will be successful in finding investment opportunities that meet these aspirational targeted returns. Although CPCI believes that the assumptions underlying such targets and returns are reasonable, future events cannot be predicted with any certainty, forecasts are not reliable indicators of future performance and there is no guarantee such targets or returns will be achieved. The scenarios presented are an estimate of future

Important Notices (cont'd)

performance based on evidence from the past as well as assumptions about current and future asset yields for such investments and projected cash flows related thereto, current and future market and economic conditions, prevailing and future interest rates, including the estimated cost leverage (where applicable), historical and future credit performance for such investments, and other factors outside the Firm's control. Investment results will vary depending on how the market performs and how long an investor keeps the investment/product. Performance targets and returns are subject to uncertainties, and the assumptions on which they are based may prove to be invalid and may change without notice. Other foreseeable events, which were not taken into account, may occur.

Upon request, Crescent will provide the criteria and assumptions upon which CPCI based performance targets and returns.

Crescent Funds may engage in speculative investment practices such as leverage, short-selling, arbitrage, hedging, derivatives, and other strategies that may increase investment loss. Crescent Cap NT Advisors, LLC serves as CPCI's investment adviser (the "Adviser"). The Adviser is an affiliate of Crescent. The Adviser's investment committee is responsible for making investment decisions for CPCI's portfolio.

Forward Looking Statement Disclosure

This report may include estimates, projections and other "forward-looking statements" within the meaning of the federal securities law. While the information and statistical data contained herein are based on sources believed to be reliable, Crescent does not represent that these are accurate and they should not be relied on as such or be the basis for an investment decision. Any opinions expressed are current only as of the time made and are subject to change without notice. Crescent assumes no duty to update any such statements. Due to numerous factors, actual events may differ substantially from those presented. Crescent, its officers, directors, employees or clients may have positions in securities or investments mentioned in this publication, which positions may change at any time, without notice.

Third-Party Information

This presentation may contain information obtained from third parties. Reproduction and distribution of third-party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. THIRD PARTY CONTENT PROVIDERS GIVE NO EXPRESS OR IMPLIED WARRANTIES, INCLUDING,

BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. THIRD PARTY CONTENT PROVIDERS SHALL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, EXEMPLARY, COMPENSATORY, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, COSTS, EXPENSES, LEGAL FEES, OR LOSSES (INCLUDING LOST INCOME OR PROFITS AND OPPORTUNITY COSTS OR LOSSES CAUSED BY NEGLIGENCE) IN CONNECTION WITH ANY USE OF THEIR CONTENT.

AIFMD

For the purposes of the Alternative Investment Fund Managers Directive ("AIFMD"), as applicable, this presentation is preliminary in nature and is not intended to constitute an offering or placement of interests in any alternative investment fund(s). Any such marketing activity will only take place once the alternative investment fund manager of such alternative investment funds has received the requisite regulatory approvals, or in circumstances in which it is otherwise permitted. Within the EEA, this presentation is intended for professional investors.

No Tax or Investment Advice

The contents of this presentation do not constitute legal, tax or investment advice.

As of Date

All information is current as of September 30, 2024 unless otherwise noted. Performance figures may be presented as preliminary and are as such until finalized by the Firm or audited by the Firm's independent certified public accountants; it is possible that adjustments may be made to such figures in connection therewith. Nevertheless, Crescent assumes no obligation to update or otherwise revised this presentation to reflect information that subsequently becomes available, or circumstances changing or occurring after such date. See Appendix for Certain Risk Factors.

Securities offered through Emerson Equity LLC Member: FINRA/SIPC. Only available in states where Emerson Equity is registered. Emerson Equities LLC is not affiliated with any other entities identified in this communication.








CPCI Overview	5
The Direct Lending Opportunity	8
Why Crescent?	15
CPCI	27



CPCI Overview



Experienced CPCI Investment Committee

Professional	Years Industry Experience	Years at Crescent	Background
CPCI Investment Committee			
 <p>Raymond Barrios President, CPCI Managing Director, Crescent</p>	22	16	TCW, Jefferies
 <p>Jason A. Breaux Chief Executive Officer, CCAP Managing Director, Crescent</p>	27	24	TCW, Salomon Brothers
 <p>Kimberly S. Grant Managing Director, Crescent</p>	26	19	TCW, Rustic Canyon Partners, Credit Suisse
 <p>Eric Hall Chief Executive Officer, CPCI Managing Director, Crescent</p>	19	17	TCW, Lehman Brothers
 <p>Christopher G. Wright Head of Private Markets Managing Director, Crescent</p>	23	23	TCW, General Electric Company

- ✓ Seasoned team of senior portfolio managers
- ✓ Multi-disciplinary skill sets broaden perspectives
- ✓ Range of 16 to 24 years experience with Crescent
- ✓ Expert ability to originate, underwrite and manage private credit

CPCI operates under the oversight of its independent Board of Directors⁽¹⁾

1. 3 of the 5 members are independent directors who are not affiliated with and do not have material business or professional relationships with Crescent Capital.

CPCI Overview

CPCI is a perpetual non-traded business development company (“BDC”) designed to generate current income with meaningful downside protection

Differentiated Investment Strategy⁽¹⁾

- Focus on **senior secured debt** in **non-cyclical** private equity backed companies
- Target companies with **\$35-\$120 million** of EBITDA with strong **free cash flow** conversion
- Core middle market focus results in **minimal overlap** with other investment managers

Cycle-Tested & Long-Tenured Platform

- **Pioneer** in private credit: 30+ year track record since 1992
- Invested over **\$41 billion** across 600+ **private credit** transactions
- **Access** to origination and underwriting capabilities of approximately **\$46 billion AUM** alternative credit platform
- Historical net loss ratio of **7 basis points** since inception⁽²⁾

Current Income & Downside Protection⁽¹⁾

- Aim to deploy capital and generate **attractive risk-adjusted returns** across market cycles
- **Low loan-to-value** ratios and high equity cushions
- Targeting **quarterly liquidity**⁽³⁾ with **monthly distributions**⁽⁴⁾

Attractive Structure⁽¹⁾

- **No public equity volatility**
- Efficient **pass-through** tax structure with **simplified 1099** tax reporting

Private Credit Specialist Backed by Sun Life

- Part of global **Sun Life Capital Management (“SLC”)** platform with **\$286 billion of AUM**⁽⁵⁾
- **\$150 million** commitment from Sun Life creates **alignment** with shareholders
- Serving the **high-net-worth (HNW)** market is a **strategic priority** for SLC Management

Note: Past performance does not guarantee or indicate future results.

Information is current as of September 30, 2024. AUM is as of December 31, 2024.

1. CPCI has limited operating history. There is no guarantee CPCI will be able to meet the objectives stated. **There is no guarantee of downside protection and losses may occur, including the loss of the entire principal amount invested.**

2. As of September 30, 2024. Refers to the total amount of net losses across all Crescent Private Credit Strategies of all Realized and Unrealized Direct Investments (as the case may be) divided by the total amount invested and further divided by the number of years elapsed from the first investment. Net loss is defined as the amount for those transactions where Total Value is less than amount invested.

3. At the discretion of its Board of Directors, CPCI intends to conduct quarterly offers to repurchase up to 5% of its outstanding common shares. There is no guarantee CPCI will be able to meet the objectives stated.

4. CPCI currently intends to pay regular monthly distributions commencing with the first full calendar quarter after it holds the first closing in the offering of common shares pursuant to its prospectus. However, any distributions CPCI makes will be at the sole discretion of its Board of Directors. As a result, CPCI's distribution rates and payment frequency may vary from time to time and are not guaranteed.


5. As of December 31, 2024.

| The Direct Lending Opportunity



Direct Lending Defined

Middle Market Direct Lending is large and growing, with advantages to lenders and borrowers



Definition

A strategy within private credit whereby non-banks **make loans directly** to private equity-backed companies

Opportunity

Leveraged buyouts, growth capital, refinancings, and recapitalizations

The middle market consists of **~200,000 private companies** that represent 1/3 of private sector GDP, employing 48 million people⁽¹⁾

Key Characteristics

Relationship-based model

Limited number of parties

Customized documentation for specific risks of each transaction

Enhanced lender protections

Borrower Benefits

Certainty and **speed** of execution

Confidentiality / no ratings required

Bespoke capital solutions to meet specific needs













Ongoing growth **support** through add-ons and upsizes

1. Year-End 2024 Middle Market Indicator, middlemarketcenter.org

Key Differences between Broadly Syndicated Loans and Direct Lending

Syndicated Debt

Direct Lending

Dozens or more 	Lenders	1 to 6+ 
\$200 million - \$5 billion+ 	Deal Size	\$20 million - \$2 billion+ 
Typically less than direct lending 	Pricing	Premium over syndicated loan yield 
Most deals now cov-lite 	Covenants	Most deals with covenants 
Tradeable except in extreme market circumstances 	Secondary Liquidity	Generally less liquid than broadly syndicated loans; lenders often plan to hold to maturity 
Typically about two months from inception; subject to market conditions 	Execution	Generally faster to execute; greater certainty without syndication process 
Added complexity due to number of lenders; potential conflicting incentives between lender groups	Workout	Potentially more simplified due to fewer lenders; unitranche structure could eliminate potential for conflicting lender groups

Direct Lending – Why Now?

Private Credit is benefiting from a combination of economic and secular trends



**Private Equity Demand
for Debt Continues to
Grow**



**Shift From Traditional
Bank Lending to Private
Credit Is Accelerating**




**Current Environment
Presents a Highly
Attractive Entry Point**

Robust Demand for Middle Market Capital

We believe private equity-backed middle market companies represent a large, attractive lending opportunity

Record levels of private equity dry powder is expected to drive robust deal activity⁽¹⁾

Private Equity & Private Credit Fund Dry Powder (\$ in billions)



Private equity dry powder far exceeds the available debt capital needed to support projected buyout activity

Note: This page is accompanied by footnotes on the page titled "Additional Footnotes" at the end of this section, which are an integral part of this presentation.


1. Preqin, as of December 31, 2024.

Private Credit Extends Beyond LBOs

Non-LBO transactions supplement traditional deal flow and expand Private Credit's opportunity set

Refinancings, growth capital, and recaps account for over half of Private Credit volume annually⁽¹⁾

% of Private Credit Deals where Use of Proceeds is Non-LBO



Note: This page is accompanied by footnotes on the page titled "Additional Footnotes" at the end of this presentation (slide 33), which are an integral part of this presentation.


1. LCD, PC & MM Q4 2024 Quarterly Stats. As of December 31, 2024.

Highly Attractive Entry Point


We believe the current market presents an opportunity for compelling returns

Private Credit has historically compared favorably to other credit asset classes...⁽¹⁾

Risk-Return (2004 - Dec. 2024)



...and is currently benefiting from elevated rates, which are expected to stay higher for longer⁽²⁾



Private credit returns are expected to remain attractive on absolute and risk-adjusted bases

Note: This page is accompanied by footnotes on the page titled "Additional Footnotes" at the end of this presentation (slide 33), which are an integral part of this presentation.

1. For illustrative purposes only. As of December 31, 2024. Private Credit (CDLI) as of September 30, 2024.

2. As of December 31, 2024. 3M SOFR – Forward Curve as of February 3, 2024. CDLI is as of September 30, 2024.

CRESCENT

Why Crescent?




A Leading Specialist Focused Exclusively on Corporate Credit

Crescent seeks to deliver attractive returns with less volatility, lower default rates and higher recovery than the market average

- Complementary strategies investing across the debt capital structure of companies of all sizes, in both private and tradeable markets
- A firm-wide philosophy prioritizing capital preservation and high current income
- Pioneering, collaborative culture with a comprehensive, research-driven approach to credit investing

Asset Mix

Tradeable Credit
\$11B AUM



Private Credit
\$35B AUM

\$46B

in assets under management

500+

client relationships⁽¹⁾

30+

year track record spanning multiple market cycles

230+

professionals

20

year average tenure of Crescent's leadership⁽²⁾

5

office locations in the U.S. and Europe

Past performance does not predict future returns.

1. Excludes GP and Affiliate relationships.

2. Crescent's Managing Partners and Executive Committee.

Why Crescent?

Crescent is a **pure play** credit specialist

Minimizes potential for conflicts and **enhances** origination pipeline

Singular Focus on Corporate Credit

Team Continuity

Team has **long track record** investing in private credit together

CPCI investment committee ranges **16 to 24 years** experience at Crescent

Cycle-Tested Track Record

Fully Integrated Credit Platform

30+ year track record spanning multiple market cycles

Historical net loss ratio of **7 basis points** since inception⁽¹⁾

Expertise spans across approximately **\$46B AUM** in Private Credit and Tradeable Credit strategies

Broad coverage of middle market **across private and public credit** enhances origination & underwriting

AUM is as of December 31, 2024.

1. As of September 30, 2024. Refers to the total amount of net losses across all Crescent Private Credit Strategies of all Realized and Unrealized Direct Investments (as the case may be) divided by the total amount invested and further divided by the number of years elapsed from the first investment. Net loss is defined as the amount for those transactions where Total Value is less than amount invested.

A Fully Integrated Platform of Complementary Credit Strategies

Crescent's private markets sponsor relationships aid tradeable market allocations, and tradeable markets research analysts aid private markets credit underwriting

Private Credit		Tradeable Credit	
Direct Lending Strategies	Multi-Asset Class Portfolios	Asset Class	Multi-Asset Class Portfolios
Crescent Credit Solutions (CCS) <i>Global core mid-market senior and junior debt</i>	Capital Trust <i>ERISA Vehicle</i>	Bank Loans <i>Broadly syndicated, floating-rate senior bank loans</i>	High Income <i>Fixed and floating-rate below investment grade credit</i>
Crescent Direct Lending (CDL) <i>U.S. lower mid-market senior debt</i>	Crescent Capital BDC, Inc. (CCAP) <i>Exchange-listed BDC</i>	High Yield Bonds <i>Publicly traded, fixed-rate bonds</i>	Syndicated Credit Solutions <i>Narrowly syndicated bank loans and bonds</i>
Crescent European Specialty Lending (CESL) <i>European lower mid-market senior debt</i>	Crescent Insurance Solutions <i>Insurance dedicated fund</i>	Structured Products <i>CLO Debt and Equity</i>	Credit Opportunities <i>Dislocation strategy</i>
	Crescent Private Credit Income Corp. (CPCI) <i>Non-traded perpetual-life BDC</i>		


Note: Crescent maintains internal information barrier policies which may require analysts to avoid disclosing certain information broadly within the Firm and/or between the private market and capital market teams. Past performance does not predict future returns.

Sophisticated Approach to Structuring Solutions for a Diverse Client Base

Crescent has expertise in structuring investment vehicles that address capital efficiency, tax and regulatory considerations

Commingled Vehicles	Customized Solutions
Limited Partnership	Separately Managed Account
Rated Notes	Fund of One
ERISA Vehicle	BDC of One
Insurance Dedicated Fund	Private CLO

Crescent's Investor Base⁽¹⁾



Note: This material is for general discussion purposes only, does not purport to be a complete description of the regulatory and tax requirements applicable to investors, and is not intended to constitute legal or tax advice or a recommended course of action in any given situation. The recipient is encouraged to consult their counsel or advisors before making any decisions or taking any action concerning the matters herein.

1. Pension Plans: Includes Public Funds, Taft-Hartley & Corporate Pensions; Sovereign Wealth: Includes Sovereign Wealth Funds, Foreign Public Funds & Superannuation Schemes.

Access to Resources of SLC Management

Crescent focuses on its expertise within its corporate credit niche while benefiting from resources and financial support of a global investment platform

150+ years

Of experience managing assets

\$286B

Assets Under Management⁽¹⁾

770+

Investment Professionals

1,400+

Clients Served

Top 100

Most sustainable corporations in the world



SLC Fixed Income

\$142B AUM

Invests across spectrum of investment grade public and private fixed income for pension plans and insurance companies

CRESCENT

\$46B AUM

Seeks credit investments in high-quality companies across a diversified range of industries

BGO

\$83B AUM

Top global ranking in the annual Global Real Estate Sustainability Benchmark for 10 consecutive years⁽²⁾

InfraRed
Capital Partners

\$13B AUM

200+ infrastructure investments under management

A·A·M
ADVISORS ASSET MANAGEMENT


\$2B AUM | \$9B AUA

Independent U.S. retail distribution firm providing solutions and products to financial professionals at warehouses, registered investment advisors and independent broker-dealers.

Note: All data as of December 31, 2024. Global financial services organization refers to Sun Life Financial. Sun Life Capital Management (U.S.) LLC., which operates under the brand name SLC Management, is the U.S. arm of the global institutional asset management business of Sun Life Financial. Sun Life has earned a spot on the Corporate Knights' Corporate Knights: 2024 Global 100 Most Sustainable Corporations in the World. Corporate Knights applies a data driven approach and assesses roughly 6,700 companies against global industry peers on a suite of up to 25 quantitative key performance indicators covering resource, employee and financial management, sustainable revenue & sustainable investment and supplier performance. Ranking was issued for Sun Life on 1/17/2024 by Corporate Knights and is based on 2022 fiscal year data.

1. The assets under management (AUM) represent the combined AUM of Sun Life Capital Management (Canada) Inc., Sun Life Capital Management (U.S) LLC, Crescent Capital Group, BGO, InfraRed Capital Partners, and Advisors Asset Management (AAM). Total AUM excludes \$9B in AAM AUA.
2. Global Real Estate Sustainability Benchmark (GRESB) awards are based on GRESB's assessment of two sustainability components. The assessment includes information on property performance indicators, such as energy consumption, greenhouse gas emissions, water consumption, and waste. Details of the questionnaire and GRESB's assessment and weighting of responses are available at <https://gresb.com/gresb-real-estate-assessment/>. Compensation, inclusive of membership fees as relevant, has been provided for survey participation, ranking and/or rating issuance as applicable.

Investing in Credit Across Market Cycles for More Than Three Decades



Deep and Experienced Crescent Team

Breadth and depth of team across below investment grade credit with over 110 investment professionals

Private Credit	Public Credit / Research	Trading
35+ Managing Directors	10 Managing Directors	1 Managing Director
5+ Senior Vice Presidents	4 Senior Vice Presidents	1 Senior Vice President
15+ Vice Presidents	2 Vice Presidents	2 Vice Presidents
25 Additional Investment Professionals	5+ Additional Investment Professionals	4 Additional Investment Professionals
<ul style="list-style-type: none"> • 80+ investment professionals • \$41+ billion invested • Assets managed through funds and SMAs 	<ul style="list-style-type: none"> • 20+ investment professionals • 15 core industry verticals • Assets managed through funds, SMAs and CLOs 	<ul style="list-style-type: none"> • 8 investment professionals • Focused and longstanding Wall Street relationships

Operations Team - Over 115 Professionals

Accounting

HR & Administration


Investor Relations

Legal & Compliance

Investment team information is as of December 31, 2024. Reflective of year-end promotions, effective January 1, 2025.
Dollars invested is as of December 31, 2024.

Robust, Proprietary Sourcing

Private Credit Deal Flow by Year




As of December 31, 2024.

Includes investment opportunities from Crescent Credit Solutions, Crescent Direct Lending and Crescent European Specialty Lending. There can be no assurance that Crescent will be able to leverage its network with respect to any future investments or invest in similar opportunities in the future.

1. Deals completed reflects new portfolio company investments and excludes add-ons.

Priority in Capital Structure Helps Provide Downside Protection

Structure and credit documentation may help protect against downside risk⁽¹⁾



Typical Downside Protection⁽¹⁾

Focus on Top of Capital Structure

Meaningful Value Cushion

Bespoke Credit Agreement including Restrictive Covenants

More Real Time Access to Information & Financials

Private Equity Sponsors Provide Capital & Support

Note: For illustrative purposes only. The above reflects Crescent's views and beliefs as of the "As of Date" noted on slide 3. The example shown above is illustrative and may not be representative of CPCI investments. Illustrations in this presentation may not be relied upon for purposes of investing in CPCI.

1. CPCI has limited operating history. There is no guarantee CPCI will be able to meet the objectives stated. **There is no guarantee of downside protection and losses may occur, including the loss of the entire principal amount invested.**

Long Dated Track Record

Longstanding partnerships built over years of working together and multiple vintages across 20+ private credit funds

Cumulative Gross Originations & Deals Closed⁽¹⁾

(\$ in billions)



\$35B

Private Credit AUM as of December 31, 2024

\$41B+

Deployed across 20+ Private Credit funds ⁽²⁾

600+

Transactions with 280+ Sponsors

<3%

Historical deal approval rate ⁽³⁾

7 bps

Historical net loss rate since inception ⁽⁴⁾

Note: Past performance does not guarantee or indicate future results.

1. Inception to date through December 31, 2023. Invested capital is aggregated by portfolio company, and all subsequent add-ons are retroactively included in the year in which the original platform investment was made. Data excludes funds managed by Crescent European Specialty Lending.
2. Private credit funds are exclusive of multi-strategy funds and separately managed accounts. As of December 31, 2024.
3. Based on the average of the last five years (2020-2024).
4. As of September 30, 2024. Refers to the total amount of net losses across all Crescent Private Credit Strategies of all Realized and Unrealized Direct Investments (as the case may be) divided by the total amount invested and further divided by the number of years elapsed from the first investment. Net loss is defined as the amount for those transactions where Total Value is less than amount invested.

Experienced BDC Manager with Track Record

Crescent is a proven manager with its initial BDC, CCAP, launched in 2015


High Quality Portfolio with Stable and Resilient NAV profile

- \$1.6 billion portfolio focused on first lien loans to sponsor-backed middle market companies
- Trades on the NASDAQ exchange (ticker: CCAP)
- Investment grade rating: BBB- (KBRA)
- Net dividend yield of ~10%⁽¹⁾

Consistent Dividend Coverage Track Record

- Cumulative adjusted net investment income per share in excess of dividends paid since inception in Q2 2015
- Regular dividend has never been cut

Stable NAV with Consistent Dividend Coverage⁽²⁾



Note: Past performance does not guarantee or indicate future results.

1. Dividend yield is calculated based on the minimum quarterly amount paid during the previous two full calendar quarters, including the most recent Q4 2024 regular dividend of \$0.42 per share, plus the Q4 variable supplemental dividend of \$0.07 per share, annualized and divided by NAV per share as of December 31, 2024.

2. As of December 31, 2024. NAV per Share for the 2015-2024 periods are the as-reported figures as of December 31 in each of those years.

CRESCENT

CPCI



CPCI Market Positioning

CPCI focuses on core of middle market in terms of yield, protections and risk profile

	EBITDA Range <i>\$ in millions</i>	Characteristics
Upper Middle Market	\$120+	<ul style="list-style-type: none">• Larger companies are potentially less risky given they are typically more diversified• Generally more borrower friendly with lower yields and less restrictive credit documentation• Can compete directly with broadly syndicated markets
CPCI Focus Core Middle Market	\$35 - \$120	<ul style="list-style-type: none">• Larger companies with more scale and business diversity• Typically receive yield premium and better lender protections• Less efficient capital markets
Lower Middle Market	\$10 - \$35	<ul style="list-style-type: none">• Smaller companies are potentially riskier given they are typically less diversified• Generally higher yields to compensate for elevated risk• Generally tighter documents and lender protections

Note: Reflects Crescent's views and beliefs. Subject to change.

Mature, Resilient Businesses

We focus on mature companies with annuity-like revenue characteristics and strong cash flows



Examples of What We Like

Recurring Cash Flows

Mission Critical Product or Service

Long, Stable Operating History

Strong Cash Flow Conversion



Examples of Why We Pass

Capital Intensive

Cyclical

Revenue-Based

Turnaround

Current Portfolio Snapshot

Portfolio At-A-Glance

\$310 million

Total Assets

132

Portfolio Companies

95%

Senior Secured

99%

Floating Rate⁽¹⁾


38%

Avg. Loan-to-Value⁽²⁾


\$66 million

Median Portfolio Company EBITDA⁽³⁾

Portfolio by Asset Class



Top 10 Industries



1. As a percentage of debt investments.
2. As of January 31, 2025. Weighted average loan-to-value ("LTV") represents the net ratio of LTV for each portfolio company, weighed based on the fair value of total applicable CPCI private debt investments. LTV is calculated as the total net debt through each respective loan tranche held by CPCI divided by the estimated enterprise value of the portfolio company as the time of underwrite. Includes directly originated debt investments only.
3. Median portfolio company EBITDA at time of underwrite. Sponsor-backed debt positions and median portfolio company EBITDA based on directly originated debt investments only.

CPCI Summary Terms

Investment Objective	To maximize the total return to our stockholders in the form of current income and, to a lesser extent, long-term capital appreciation through debt and related equity investments.		
Structure	Non-listed business development company that is perpetually offered		
Term	Perpetual life; CPCI does not intend to seek an IPO or other liquidity event		
Subscriptions	Monthly at NAV (fully funded)		
Intended Distribution Frequency⁽¹⁾	Monthly (distributions are not guaranteed, may represent a return of capital and may be paid from sources other than cash flow from operations)		
Liquidity⁽²⁾⁽³⁾	Up to 5%/quarter, 20%/year (share repurchase plan)		
Leverage⁽⁴⁾	Target 1.0x to 1.25x debt-to-equity; 2.0x regulatory cap		
Management Fee	1.25% per annum on net assets		
Incentive Fee⁽⁵⁾⁽⁶⁾	12.5% of net investment income subject to a 5% hurdle, paid quarterly; 12.5% of realized capital gains net of realized and unrealized losses, paid annually		
Tax Reporting	Form 1099-DIV		
Share Classes	Class S	Class D	Class I
Upfront Placement Fee	Up to 3.5%	Up to 1.5%	None
Ongoing Service Fee⁽⁷⁾	0.85% of net asset value (annualized)	0.25% of net asset value (annualized)	None
Minimum Investment	\$2,500	\$2,500	\$1,000,000

This information is summary in nature and is in no way complete, and these terms have been simplified. This information omits certain important details about the stated terms and does not address certain other key Fund terms or risks or represent a complete list of Fund terms. If you express an interest in investing in the fund, you will be provided with a prospectus, subscription agreement, and other documents ("Fund Documents"), which shall govern in the event of any conflict with the general terms listed herein. You must rely only on the information contained in the Fund Documents in making any decision to invest. Please see the prospectus for corresponding terms.

CPCI Summary Terms – Footnotes

1. Distribution payments are not guaranteed. Crescent Private Credit Income Corp. may pay distributions from sources other than cash flow from operations, including, without limitation, the sale of assets, borrowings, return of capital or offering proceeds, and advances or the deferral of fees and expense reimbursements.
2. We do not intend to list our shares on a securities exchange, and we do not expect there to be a public market for our shares. As a result, if you purchase shares of our common stock, your ability to sell your shares will be limited. Our board of directors reserves the right, in its sole discretion, to limit the number of shares to be repurchased for each class by applying the limitations on the number of shares to be repurchased on a per class basis. All shares purchased by us pursuant to the terms of each offer to repurchase will be retired and thereafter will be authorized and unissued shares. We intend to limit the number of shares to be repurchased in each quarter to no more than 5.0% of our outstanding shares of common stock.
3. Any periodic repurchase offers are subject in part to our available cash and compliance with the BDC and RIC qualification and diversification rules promulgated under the 1940 Act and the Code, respectively. While we intend to continue to conduct quarterly repurchase offers as described above, we are not required to do so and may suspend or terminate the share repurchase program at any time.
4. Represents CPCI's expectations for leverage. Actual metrics are subject to change based on market conditions and may deviate from this target at various times.
5. An incentive fee on net investment income, which we refer to as the incentive fee on income, will be calculated and payable quarterly in arrears and will be based upon our pre-incentive fee net investment income for that immediately preceding calendar quarter. The quarterly incentive fee on net investment income is (a) 100% of the pre-incentive fee net investment income between 1.25%, which we refer to as the quarterly preferred return, and 1.43%, which we refer to as the upper-level breakpoint, of CPCI's net asset value for that immediately preceding calendar quarter plus (b) 12.50% of all remaining pre-incentive fee net investment income in excess of the upper lever breakpoint for that calendar quarter. Pre-incentive fee net investment income is defined as investment income and any other income, accrued during the previous calendar quarter, minus operating expenses for the quarter, including the base management fee, expenses payable under the Investment Advisory Agreement and the Administration Agreement, any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee. Pre-incentive fee net investment income does not include any expense support payments or any reimbursement by CPCI of expense support payments, or any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. The quarterly preferred return of 1.25% and upper-level breakpoint of 1.43% are also adjusted for the actual number of days in each calendar quarter.
6. An incentive fee on capital gains will be determined and payable in arrears as of the end of each calendar year. It will be equal to (i) 12.50% of our realized capital gains on a cumulative basis from inception through the end of such calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less (ii) the aggregate amount of any previously paid incentive fees on capital gains as calculated in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). To be paid by the investor.
7. Ongoing Service Fee, together with the Maximum Upfront Sales Load, to be capped at 10% of gross proceeds or such other lower amount as Crescent may negotiate with its distribution partners.

Additional Footnotes

“Robust Demand for Middle Market Capital”

- 1) Dry powder is defined as the sum of uncalled capital commitments which GPs will have to invest. Private Equity dry powder includes Buyout strategy only. Private Credit dry powder includes Direct Lending and Mezzanine strategies only.

“The Industry Is Shifting to Private Credit”

- 1) Includes Asian, Canadian, European, and U.S. bank share from 1994-2022. 2023 is shown for illustrative purposes and is based on Crescent estimate.
- 2) Data is based on the count of transactions financed in the Syndicated and Private Credit markets. Count is based on transactions covered by LCD News.
- 3) The Basel Committee on Banking Supervision (BCBS) had issued final Basel III reforms in December 2017, followed by the final market risk capital requirements standard in January 2019. The implementation date for these final reforms were extended by one year to January 1, 2023 in the backdrop of the COVID-19 pandemic.

“Highly Attractive Entry Point”

- 1) Volatility is measured using standard deviation. All of the quarterly standard deviations are then annualized. Indices: “Private Credit” is represented by the Cliffwater Direct Lending Index. “Leveraged Loans” is represented by the Morningstar LSTA U.S. Leveraged Loan Index. “High Yield” is represented by the Bloomberg U.S. Corporate High Yield Index. “Investment Grade Bonds” is represented by the Bloomberg U.S. Aggregate Bond Index. “Public Equities” is represented by the S&P 500 Total Return Index.
- 2) High Yield: Represents Current Yield for the Bloomberg U.S. Corporate High Yield Index, calculated as index coupon divided by index price (Source: Bloomberg). LL Index: Represents Current Yield for the Morningstar LSTA Leveraged Loan Index (Source: LCD). CDLI: Represents the Current Yield for the Cliffwater Direct Lending Index (Source: Cliffwater 2024 Q2 Report on U.S. Direct Lending). Historical and forward 3M SOFR curves per Bloomberg. Private Equity: Represents 2009-2017 vintages (Source: 2022 Preqin Global Private Debt Report).

Certain Risk Factors

Nature of Debt Securities. Debt and structured equity investments in highly leveraged companies involve a high degree of risk with no certainty of any return of capital. The debt securities in which CPCI invests may be unsecured and subordinated to substantial amounts of senior debt, all or a portion which may be secured, may not be protected by financial covenants or limitations on additional debt, may have limited liquidity. CPCI invests in securities that are rated below investment grade by rating agencies or that would be rated below investment grade if they were rated. Bonds that are rated below investment grade are sometimes referred to as “high yield bonds” or “junk bonds.” Below investment grade securities have predominantly speculative characteristics with respect to the issuer’s capacity to pay interest and repay principal. They may also be illiquid and difficult to value.

Competitive Debt Environment. CPCI competes with the public debt and equity markets and with other investors for suitable investment opportunities. There can be no assurance that CPCI will be able to locate and complete investments, fully invest its committed capital or satisfy its rate of return objectives.

Foreign Investments. Investments in non-U.S. companies involve risks not typically associated with the more developed U.S. capital markets, including risks relating to currency exchange, differences between the U.S. and foreign securities markets, differences in corporate and creditors’ rights laws and economic, and political risks.

Financial Markets. Instability in the securities markets may increase the risk inherent in CPCI’s investments in that the ability of portfolio companies to refinance or redeem debt and structured equity securities held by CPCI may depend on its ability to sell new securities in the market.

No Assurance of Investment Return. There can be no assurance that CPCI will be able to generate returns for its investors or that the returns will be commensurate with the risks of investing in the type of companies and transactions described herein. Accordingly, an investment in CPCI should only be considered by persons who can afford a loss of their entire investment. Past activities or investment return results of investment entities associated with the Crescent management team or its principal members, including their prior funds, provide no assurance of future success or return results. The fees and expenses charged in connection with an investment in CPCI may be higher than the fees and expenses of other investment alternatives and may offset profits.

Use of Leverage. CPCI may leverage the cost of its investments. To the extent CPCI purchases securities with borrowed funds, its net assets will tend to increase or decrease at a greater rate than if borrowed funds are not used. If the interest expense on borrowings were to exceed the net return on the portfolio of securities purchased with borrowed funds, CPCI’s use of leverage would result in a lower rate of return than if CPCI was not leveraged. Overall, the use of leverage, while providing the opportunity for higher returns, also increases volatility and the risk of loss.

No Regulatory Approval. CPCI has not been approved or disapproved by any

securities regulatory authority of any state, by the Securities and Exchange Commission, or any similar authority in another jurisdiction.

Interest Rate Fluctuations. Interest rate fluctuations may negatively impact CPCI’s investment opportunities and the rate of return on invested capital. An increase in interest rates would make it more expensive for portfolio companies to finance operations and indirectly affect the credit quality of CPCI’s investments.

Lack of Diversification and Reliance on Portfolio Company Management. CPCI may invest in a limited number of investments and may be concentrated in only a few industries. Therefore, the aggregate return of CPCI may be adversely affected by the negative performance of a relatively few investments. The manager monitors portfolio company performance; however, it is primarily the responsibility of portfolio company management to operate a portfolio company on a day to day basis and there is no assurance that such management will perform in accordance with CPCI’s expectations.

Dependence Upon Key Personnel. Decisions with respect to the investments and management of CPCI will be made exclusively by the Crescent management team. Investors generally have no right to take part in the management of CPCI and do not have an opportunity to evaluate the specific investments made by CPCI or their terms. The success of CPCI depends significantly upon the skill and expertise of the principal members of the Crescent management team. The departure of any of those principal members, as well as potential resignation of CPCI’s investment adviser and/or administrator, could have a material adverse effect on CPCI.

Conflicts of Interest. Crescent and its affiliates manage multiple funds and accounts. Key personnel will devote some business time to managing those other funds and accounts. Obligations to certain funds and accounts could in certain circumstances adversely affect the price paid or received for investments by CPCI or the size or the portion of investments purchased by CPCI.

No Market for CPCI Interests. CPCI’s common shares are expected to be continuously offered on a “best efforts” basis, which means generally that the intermediary manager is required to use only its best efforts to sell the shares and it has no firm commitment or obligation to purchase any of the shares. CPCI does not intend to list its common shares on any national securities exchange, and neither its intermediary manager nor the participating brokers intend to act as market-makers with respect to CPCI’s common shares. Because no public market is expected for CPCI’s common shares, stockholders will likely have limited ability to sell their shares until there is a liquidity event for CPCI. At the discretion of CPCI’s Board of Directors and beginning no later than the first full calendar quarter after CPCI holds the first closing in its public offering of common shares, CPCI intends to commence a share repurchase program in which CPCI intends to offer to repurchase up to 5% of its outstanding common shares (either by number of shares or aggregate NAV) in each quarter. CPCI expects to repurchase such shares using a purchase price equal to NAV per share as of the last calendar day of the applicable month designated by CPCI’s Board of Directors, except that CPCI will deduct 2.00% from such NAV for shares that have not been outstanding for at least one year.